UroGen Pharma Ltd. (NASDAQ:URGN) has unveiled the design of its pivotal uTRACT Registry study at the 2025 American Society of ...

We know from the phase 2 TROPHY-U-01 trial that sacituzumab govitecan is an active drug, with an objective response rate of ...

Investigators used the Shiny method, which employs artificial intelligence, to indirectly compare the efficacy of novel systemic therapies for urothelial cancer using phase 3 trial data.

Complete response (CR) observed in 73% (27/37) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who ...

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights the presentation of the ...

The CheckMate 901 trial compared Opdivo-Yervoy with gemcitabine-carboplatin for cisplatin-ineligible metastatic urothelial carcinoma patients. Despite negative trial results, the FDA approved Opdivo ...

Urothelial carcinoma is cancer of the urinary system. The urothelium is a kind of epithelial (protective) lining of the urinary system, which includes the urinary tract, bladder, your ureters (the ...

Annual Meeting held in Chicago, IL, was host to a State of the Science session on novel diagnostics and therapeutics in renal cell and urothelial carcinomas. Dr. Wulff-Burchfield discussed strategies ...

Chinese-herb nephropathy is a progressive form of renal fibrosis that develops in some patients who take weight-reducing pills containing Chinese herbs. Because of a manufacturing error, one of ...

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers ...

Results from a small retrospective analysis of patients with upper tract urothelial carcinoma lesions were shared at the 2025 ASCO Genitourinary Cancers Symposium. Among patients with upper tract ...

which demonstrated survival improvements for patients treated with enfortumab vedotin and pembrolizumab that were previously unprecedented in locally advanced or metastatic urothelial cancer.